Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US30161Q1040
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BL3220
EXEL
Exelixis Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Exelixis Inc
ISIN
US30161Q1040
TICKER
EXEL
MIC
XNAS
REUTERS
EXEL.OQ
BLOOMBERG
EXEL US
Mon, 11.08.2025       Exelixis
US30161Q1040

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.08.2025       Exelixis
US30161Q1040

NEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.07.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least o...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.07.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available vi...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.07.2025       Exelixis
US30161Q1040

Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /CNW/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.06.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously t...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.06.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroen...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These fi...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 13.05.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by acceleratin...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities 2025 Health Care Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 14 in Las Vegas. RBC Capital Markets 2025 Global Healthcare Confer...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.04.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.03.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.03.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL. “We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our co...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.02.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 45th Annual Health Care Conference: Exelixis is scheduled to present at 9:50 a.m. ET / 6:50 a.m. PT on Tuesday, March 4 in Boston. Barclays 27th Annual Global Healthcare Conference:...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.02.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans on completing the currently ongoing $500 million stock repurchase program (SRP), announced in August 2024, in the second quarte...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Sat, 15.02.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). After more than five years of follow-up, the findings demonstrated that e...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.02.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News headin...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.02.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis delivered a strong fourth quarter of 2024, positioning us well to maximize su...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 28.01.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the ev...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.01.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab (Tecentriq®) in patients with previously-treated metastatic colorectal cancer (CRC). The findings will be presented during Poster Session C: Cancers of the Colon, Rect...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.01.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract. The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.01.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as well as m...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.01.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer b...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.01.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT. To access the webcast link, log onto www.exelixis.com and proceed t...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.11.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global Healthcare Confe...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.11.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will b...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.11.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim’s Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston. Stifel 2024 Healthcare Conference...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones. “The favorable ruling on our cabozantinib intellectual property estate and recentl...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to three Orange Book-listed patents related to cabozantinib...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.10.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis’ investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrol...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.09.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with advanced pancreatic neuroendocrine tumors (pNET) and one cohort with advanced extra-pancreatic NET (...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Sun, 15.09.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (Tecentriq®) compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measu...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.08.2024       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 9:15 a.m. ET / 6:15 a.m. PT on Wednesday, September 4 in New York City. 2024 Wells Fargo Heal...
Read more
Exelixis
Technical Analysis Termsheets Terminal
Permalink